Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can two heart drugs cut HIV Patients' cardiac risk?

NCT ID NCT06317051

First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 18 times

Summary

This study tests if adding dapagliflozin (a diabetes drug) or a specific statin combo can help people with HIV who have gained weight and have high cholesterol. About 300 adults aged 40-75 on common HIV meds will be randomly assigned to receive either dapagliflozin or a placebo, and either a statin combo or another statin. The goal is to see if these drugs can reduce weight and bad cholesterol, potentially lowering heart disease risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Austin Health

    Melbourne, Victoria, 3084, Australia

  • CART-CRS

    Chennai, Tamil Nadu, 600113, India

  • Desmond Tutu Health Foundation

    Cape Town, 7925, South Africa

  • HIV-NAT

    Bangkok, Thailand

  • Hospital Ramos Mejía

    Buenos Aires, Argentina

  • Infectious Diseases Institute, Makerere University

    Kampala, Uganda

  • Institute of Human Virology, Nigeria

    Abuja, Nigeria

  • St Vincent's Hospital

    Sydney, New South Wales, 2010, Australia

  • Universiti Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • University of Zimbabwe Clinical Research Centre

    Harare, Zimbabwe

Conditions

Explore the condition pages connected to this study.